Work

Study design of ESCAPE-TRD, a long-term, comparative, randomised phase IIIb clinical trial of esketamine nasal spray in treatment resistant depression

Year: 2022

Type: article

Source: Neuroscience Applied

DOI: 10.1016/j.nsa.2022.100638

Authors: A. Reif, T. Messer, P. Eckhard, K. Heerlein, R. Milz, K. Olbrich, B. Rive, G. Van Dooren, C. von Holt, R. Wapenaar, Y. Godinov

Institutions: University Hospital Frankfurt, Technical University of Munich, Janssen (Germany), Janssen (France), Janssen (Belgium), Janssen (Netherlands), Bulgarian National Bank

Language: English

Topic: Treatment of Major Depression

Subfield: Pharmacology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,000

OpenAlex ID: W4313201214

FWCI:

Cites:

Cited by:

Related to: 10